Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024

6/17/24 8:41:36 AM ET

$EVOK

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EVOK alert in real time by email

Expanded State Medicaid Access for GIMOTI

Achieved highest ever monthly GIMOTI prescription fills in May 2024

Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer

SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation.

Get the next $EVOK alert in real time by email

Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024

Chat with this insight

Recent Analyst Ratings for
$EVOK

$EVOK
Financials

Live finance-specific insights

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

$EVOK
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for GIMOTI

$EVOK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

Amendment: SEC Form SC 13D/A filed by Evoke Pharma Inc.

$EVOK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Nantahala Capital Management, Llc claimed ownership of 148,194 shares (SEC Form 3)

SEC Form 4 filed by Director Smeal Benjamin C.

New insider Smeal Benjamin C. claimed no ownership of stock in the company (SEC Form 3)

$EVOK
Press Releases

Fastest customizable press release news feed in the world

$EVOK
SEC Filings

$EVOK
Leadership Updates

Live Leadership Updates

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

SEC Form 10-Q filed by Evoke Pharma Inc.

Evoke Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Evoke Pharma Inc. filed SEC Form 8-K: Other Events

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Evoke Pharma Appoints Vickie Reed to Board of Directors

$EVOK
Market Insights

Live Market Insights